• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·6849.T
Share

Nihon Kohden Corporation Stocks

¥ 1586.5Last Updated 27.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

¥ 1.59B

¥ 1586.5
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nihon Kohden Corporation, founded in 1951 and headquartered in Tokyo, Japan, is a global leader in healthcare technology. The company’s core operations encompass the research, development, manufacturing, sales, repair, and maintenance of advanced medical electronic equipment, serving markets across Japan, the Americas, Europe, Asia, and other international regions. Its extensive product range features sophisticated physiological measurement instruments, including electroencephalographs (EEGs), electrocardiographs (ECGs), evoked potential and electromyogram (EMG) systems, and polygraphs for cardiac catheterization laboratories. These offerings are integrated with diagnostic information systems and supported by essential consumables like recording papers, electrodes, and catheters, along with comprehensive maintenance services. Nihon Kohden also delivers cutting-edge patient monitoring solutions, such as central, bedside, and wireless monitors, alongside remote access software. These are seamlessly linked with clinical information systems and provided with associated disposables, including various electrodes and sensors. The company's therapeutic device portfolio includes critical equipment like defibrillators (including automated external defibrillators or AEDs), ventilators, pacemakers, anesthesia machines, and cochlear implants. Necessary consumables, such as AED pads and batteries, and related services are also supplied for these products. Furthermore, Nihon Kohden offers other specialized medical apparatus, such as hematology and clinical chemistry analyzers, ultrasound diagnostic equipment, and tools for research purposes. These are accompanied by consumables like test reagents, installation services, and ongoing maintenance. Beyond its primary focus on medical devices, the corporation also participates in insurance brokerage and technology licensing.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 6849.T is 1691 and suggests 5.86% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 08:30

Wall Street has identified Broadcom as a major beneficiary of Anthropic's IPO. Who else stands to gain?

28.10.2026 08:01

"Too Big a Chicken": McDonald's Partners Deem the New Menu a Failure

28.10.2026 07:01

Healthcare stocks have become a bet against AI. Should you buy them?

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026